501684-31-7

Upstream product

• 501684-29-3 4-(3-chloro-4-fluoro-phenylamino)-7-(3-chloro-propoxy)-6-nitro-quinoline-3-carbonitrile 
• 501684-28-2 4-chloro-7-(3-chloropropoxy)-6-nitroquinoline-3-carbonitrile 
• 501684-27-1 7-(3-chloro-propoxy)-4-hydroxy-6-nitroquinoline-3-carbonitrile 
• 501684-26-0 (E)-2-Cyano-3-(3-methoxy-4-nitro-phenylamino)-acrylic acid ethyl ester 
• 214470-27-6 7-methoxy-4-hydroxy-6-nitroquinoline-3-carbonitrile 
• 536-90-3 m-Anisidine 
• 919482-02-3 4-hydroxy-7-(3-morpholin-4-yl-propoxy)-6-nitro-quinoline-3-carbonitrile 
• 919482-04-5 4-chloro-7-(3-morpholin-4-yl-propoxy)-6-nitro-quinoline-3-carbonitrile 
• 501684-30-6 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-6-nitro-quinoline-3-carbonitrile 

Relevant academic research and scientific papers

Inhibition of Tpl2 kinase and TNFα production with quinoline-3-carbonitriles for the treatment of rheumatoid arthritis

The synthesis and structure-activity studies of a series of quinoline-3-carbonitriles as inhibitors of Tpl2 kinase are described. Potent inhibitors of Tpl2 kinase with selectivity against a panel of selected kinases in enzymatic assays and specificity in cell-based phosphorylation assays in LPS-treated human monocytes were identified. Selected inhibitors with moderate activity in human whole blood assay effectively inhibited LPS/D-Gal induced TNFα release when administered intraperitoneally in mice.

Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: Analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents

The syntheses and biological evaluations of 4-anilinoquinoline-3-carbonitrile analogues of the three clinical lead 4-anilinoquinazolines Iressa, Tarceva, and CI-1033 are described. The EGFR and HER-2 kinase inhibitory activities and the cell growth inhibition of the two series are compared with each other and with the clinical lead EKB-569. Similar activities are observed between these two series.